NCT03871907 is a NA clinical trial of Digital technology in Coronary Artery Disease, sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences.

Who is sponsoring NCT03871907?

NCT03871907 is sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences.

What drugs are being tested in NCT03871907?

Interventions in NCT03871907: Digital technology.

What condition does NCT03871907 study?

NCT03871907 studies Coronary Artery Disease.

Is NCT03871907 still recruiting?

NCT03871907 is currently completed. Last updated 27 April 2022.

Last reviewed 2022-04-27 · How we verify

NCT03871907

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Digital Technologies on Risk Factor Modification

Completed NA Last updated 27 April 2022

What this trial tests

NA trial testing Digital technology in Coronary Artery Disease in 700 participants. Completed in 1 December 2021.

Timeline

11 March 2019

Primary endpoint
31 December 2020

1 December 2021

Quick facts

Lead sponsor	Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	700
Start date	11 March 2019
Primary completion	31 December 2020
Estimated completion	1 December 2021
Sites	1 location across Russia

Drugs / interventions tested

Digital technology

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Who can join

Adults 18 to 75, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

DigTech investigates the effect of a text message-based intervention to encourage lifestyle change on objective measures of cardiovascular risk in individuals with coronary heart disease (CHD) after percutaneous coronary intervention (PCI). DigTech will recruit 700 participants from 18-75 years old with CHD after PCI. Half of the participants will be randomised into a 24 week intervention trial, which includes sending 4 personalized short messages about risk factors modification 4 times per week and the other half will be controls. Participants will complete 3 main study visits: * Visit 1: Baseline visit conducted at the beginning of the study * Visit 2: Randomization * Visit 3: End of study (24 weeks). Each visit will repeat the same set of cardiovascular measures including information about previous treatment, blood pressure, ECG, echocardiography, stress tests, blood sampling, International Physical Activity Questionnaires (IPAQ) and other measures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Digital technology

Trials testing the same drug.

NCT06652880 — Digital Support Intervention for Pregnant People with Opioid Use Disorders · EARLY_PHASE1 · active not recruiting

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Tomsk National Research Medical Center of the Russian Academy of Sciences trials

Trials by the same sponsor.

NCT07457541 — Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI · Phase 1 · active not recruiting
NCT07475390 — 99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging · NA · active not recruiting
NCT07292571 — Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107 · Phase 2 · enrolling by invitation
NCT07275463 — [99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression · Phase 2 · enrolling by invitation
NCT07018895 — Personalized Hypoxic-hyperoxic Preconditioning in Elderly People · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03871907 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tomsk National Research Medical Center of the Russian Academy of Sciences
Last refreshed: 27 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03871907.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing